These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23322619)

  • 1. Muscle cramps and weakness after teriparatide therapy: a new drug-induced myopathy?
    Luigetti M; Capone F; Monforte M; Di Lazzaro V
    Muscle Nerve; 2013 Apr; 47(4):615. PubMed ID: 23322619
    [No Abstract]   [Full Text] [Related]  

  • 2. Debilitating muscle cramps after teriparatide therapy.
    Kakaria PJ; Nashel DJ; Nylen ES
    Ann Intern Med; 2005 Feb; 142(4):310. PubMed ID: 15710971
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous vascular calcifications secondary to treatment with teriparatide.
    Leis-Dosil VM; Rubio-Flores C; Ruiz-Bravo Burguillos E; Díaz-Díaz RM
    Actas Dermosifiliogr; 2013 Jan; 104(1):87-8. PubMed ID: 22840755
    [No Abstract]   [Full Text] [Related]  

  • 4. Statin-associated myopathy with normal creatine kinase levels. Case report from a Norwegian family.
    Trøseid M; Henriksen OA; Lindal S
    APMIS; 2005 Sep; 113(9):635-7. PubMed ID: 16218940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. I used to take a statin, but developed myopathy and stopped. That was two years ago, but I still have muscle pain and weakness in my legs. Is there a solution or is this permanent damage?
    Heart Advis; 2012 Jun; 15(6):8. PubMed ID: 22838041
    [No Abstract]   [Full Text] [Related]  

  • 6. [Tremors, cramps, and myalgia after the use of ephedrine].
    González Rodríguez JL; Mateos Arribas MT
    Rev Esp Anestesiol Reanim; 2002 Nov; 49(9):501-2. PubMed ID: 12516500
    [No Abstract]   [Full Text] [Related]  

  • 7. Comments on Initial experience with teriparatide in the United States.
    Harper KD; Krege JH; Marcus R; Mitlak BH
    Curr Med Res Opin; 2006 Oct; 22(10):1927. PubMed ID: 17022851
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonuremic calciphylaxis in a patient with rheumatoid arthritis and osteoporosis treated with teriparatide.
    Dominguez AR; Goldman SE
    J Am Acad Dermatol; 2014 Feb; 70(2):e41-2. PubMed ID: 24438979
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuromuscular symptoms and elevated creatine kinase after statin withdrawal.
    Echaniz-Laguna A; Mohr M; Tranchant C
    N Engl J Med; 2010 Feb; 362(6):564-5. PubMed ID: 20147729
    [No Abstract]   [Full Text] [Related]  

  • 11. Probable osteosarcoma risk after prolonged teriparatide treatment: comment on the article by Saag et al.
    Tastekin N; Zateri C
    Arthritis Rheum; 2010 Jun; 62(6):1837; author reply 1837-8. PubMed ID: 20191586
    [No Abstract]   [Full Text] [Related]  

  • 12. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis.
    Tashjian AH; Gagel RF
    J Bone Miner Res; 2006 Mar; 21(3):354-65. PubMed ID: 16491282
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute, generalised but transient muscle cramping and weakness shortly after first oxaliplatin infusion.
    Krexner E; Stickler A; Prainer C; Finsterer J
    Med Oncol; 2012 Dec; 29(5):3592-3. PubMed ID: 22669568
    [No Abstract]   [Full Text] [Related]  

  • 14. Creatine supplementation prevents statin-induced muscle toxicity.
    Shewmon DA; Craig JM
    Ann Intern Med; 2010 Nov; 153(10):690-2. PubMed ID: 21079234
    [No Abstract]   [Full Text] [Related]  

  • 15. Teriparatide: new indication. During corticosteroid therapy: no fewer clinical fractures. Unnecessarily inconvenient.
    Prescrire Int; 2009 Aug; 18(102):159. PubMed ID: 19743573
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
    Hashimoto Y; Wakayama N; Miyauchi A
    Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levamisole-induced myopathy and leukocytoclastic vasculitis: a case report and literature review.
    Tsai MH; Yang JH; Kung SL; Hsiao YP
    Dermatol Ther; 2013; 26(6):476-80. PubMed ID: 24552411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in diagnosing hydroxychloroquine myopathy during the COVID-19 pandemic.
    Pamphlett R; Wang MX; Chan RC
    Intern Med J; 2020 Dec; 50(12):1559-1562. PubMed ID: 33354884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New bone density conservation agents for osteoporosis under research and development: PTH (1-34)].
    Endo I; Matsumoto T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():443-6. PubMed ID: 18161146
    [No Abstract]   [Full Text] [Related]  

  • 20. Anabolic therapy in glucocorticoid-induced osteoporosis.
    Sambrook PN
    N Engl J Med; 2007 Nov; 357(20):2084-6. PubMed ID: 18003966
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.